Resources
6 Results (showing 1 - 6)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 2/23/2021 (updated 4/4/2024)
RCORP Planning 3 Reference Guide
Posted 12/29/2020 (updated 4/4/2024)
Whereas outpatient treatment with medication for opioid use disorder (MOUD) is evidence based, there is a large network of inpatient facilities in the US that are reimbursed by commercial insurers and do not typically offer MOUD. This study is a comparison of rates of overdose and hospitalization after initiation of medication for Opioid Use Disorder in the inpatient vs outpatient setting.
Posted 10/18/2021 (updated 4/3/2024)
The MOUD Best Practices Webinar series takes a person-centered, outcomes-focused approach to presenting and discussing best practices in the use of medication for opioid use disorder (MOUD), starting with client engagement and initiation of MOUD, patient stabilization and retention in MOUD, and supporting recovery during MOUD. The focus of each presentation in the series will be on the application of best practices to meet your community’s goals for each of the three topic areas, including adapting them to your local resources while maintaining fidelity to their evidence base.
At the conclusion of Session 2 participants will be able to: describe specific best practices related to stabilization and retention in MOUD, connect best practices to the community’s outcomes and goals and adapt best practices to local needs and resources while maintaining fidelity to the evidence base
Presenter: Melinda Campopiano, MD (mcampopiano@jbsinternational.com)
Posted 10/23/2020 (updated 4/3/2024)
These pilot study results suggest comparable safety and effectiveness of unobserved and office induction and point toward utilization of non-inferiority design during future definitive protocol development.
Posted 10/23/2020 (updated 4/3/2024)
This article offers data regarding offering buprenorphine treatment at a public hospital primary care setting using a home, unobserved induction protocol.
Posted 12/21/2022 (updated 3/27/2024)
The Substance Abuse and Mental Health Services Administration released a notice of proposed rulemaking that would allow certified opioid treatment programs to begin prescribing the drug via audio-only or video-enabled telehealth. See additional information under Policy Updates below. The proposed changes come on top of recent findings by HHS of the positive impact of its revised Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder that removed two longstanding requirements for obtaining a waiver to treat up to 30 patients with buprenorphine: 1) the requirement for specific training, and 2) the need for otherwise eligible clinicians to certify their ability to provide or refer patients for counseling and other services. Rural primary care providers have obtained the DEA waiver at a lower rate than urban clinicians; decreased burden and greater flexibility in the guidelines, along with broader use of telehealth could help close that gap.